Bibliographic Details
| Title: |
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. |
| Authors: |
Madruga, José Valdez, Berger, Daniel, McMurchie, Marilyn, Suter, Fredy, Banhegyi, Denes, Ruxrungtham, Kiat, Norris, Dorece, Lefebvre, Eric, de Béthune, Marie-Pierre, Tomaka, Frank, De Pauw, Martine, Vangeneugden, Tony, Spinosa-Guzman, Sabrina |
| Source: |
Lancet. 7/7/2007, Vol. 370 Issue 9581, p49-58. 10p. 4 Charts, 4 Graphs. |
| Subjects: |
Clinical trial registries, HIV infections, Therapeutics, HIV-positive persons, Protease inhibitors, Clinical drug trials, Health outcome assessment |
| Abstract: |
This article reports on a clinical trial studying the efficacy and safety of darunavir-ritonavir compared with lopinavir-ritonavir at 48 weeks in treatment-experienced HIV-infected patients in TITAN: a randomised controlled phase III trial. The protease inhibitor darunavir has been shown to be efficacious in highly treatment-experienced HIV patients. This study looks at the comparison of darunavir with lopinavir in treatment-experienced lopinavir-naive patients. The study found that in treatment-experienced patients, darunavir was non-inferior to lopinavir treatment in terms of the virological endpoint and can therefore be considered as a treatment for this population. |
| Database: |
Psychology and Behavioral Sciences Collection |
